Pravachol vs. Livalo
See how Pravachol and Livalo compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Pravachol (pravastatin) is a low-to-moderate intensity statin backed by more than three decades of heart attack and stroke prevention data, and it is now sold only as a low-cost generic.
Livalo (pitavastatin) is a newer statin approved for mixed dyslipidemia with minimal CYP3A4 drug interactions, but it remains a costlier brand-only medication.
Both drugs are taken once daily by mouth and share the muscle pain and liver enzyme risks common to all statins, though the two labels report different specific rates.
Pravachol vs. Livalo Drug Summary
Pravachol
Pravachol (pravastatin) is a statin, an HMG-CoA reductase inhibitor, used to lower LDL cholesterol and triglycerides and to reduce the risk of heart attack, stroke, and cardiovascular death. It is taken as an oral tablet once daily, with or without food, usually starting at 40 mg.
Livalo
Livalo (pitavastatin) is also a statin, an HMG-CoA reductase inhibitor, used to lower LDL cholesterol, total cholesterol, apolipoprotein B, and triglycerides in adults with high cholesterol or mixed dyslipidemia. It is taken as an oral tablet once daily, typically starting at 1 mg and increasing up to 4 mg if needed.
Pravachol vs. Livalo Side Effects
Pravachol
Livalo
Pravachol vs. Livalo Dosage
Pravachol
Livalo
| STAGE | DOSE | WHEN |
| Starting dose | 40 mg once daily | At the start |
| Maximum dose | 80 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 1 mg once daily | At the start |
| Maximum dose | 4 mg once daily | If needed |
| Dose changes | 2 increases | As tolerated |
Pravachol
| STAGE | DOSE | WHEN |
| Starting dose | 40 mg once daily | At the start |
| Maximum dose | 80 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Livalo
| STAGE | DOSE | WHEN |
| Starting dose | 1 mg once daily | At the start |
| Maximum dose | 4 mg once daily | If needed |
| Dose changes | 2 increases | As tolerated |
Pravachol vs. Livalo Indications
Pravachol
Pravachol is FDA-approved to lower LDL cholesterol and triglycerides in adults and in children 8 and older with certain inherited high cholesterol. It also carries specific approval to reduce the risk of heart attack, stroke, and cardiovascular death in people with or without existing heart disease.
Adjunct to diet to lower LDL-C, total cholesterol, and triglycerides
Reduces risk of heart attack, stroke, and revascularization in primary prevention
Reduces risk of coronary death in patients with existing heart disease
Treats heterozygous familial hypercholesterolemia in children ages 8-18
Lowers triglycerides in patients with hypertriglyceridemia
Livalo
Livalo is FDA-approved to lower LDL cholesterol, total cholesterol, apolipoprotein B, and triglycerides in adults with primary hyperlipidemia or mixed dyslipidemia. It is also approved for heterozygous familial hypercholesterolemia in adults and children 8 and older, though its label does not include specific heart attack or stroke risk-reduction claims.
Adjunct to diet to lower LDL-C, total cholesterol, apoB, and triglycerides
Treats primary hyperlipidemia and mixed dyslipidemia
Treats heterozygous familial hypercholesterolemia in adults
Treats heterozygous familial hypercholesterolemia in children 8 and older
Off-label: sometimes used for primary prevention of ASCVD
Pravachol vs. Livalo Pros and Cons
Pravachol
Pravachol has one of the longest track records of any statin, with trial data going back to the early 1990s linking it to fewer heart attacks and lower cardiovascular death. As a generic, it is widely covered by insurance and inexpensive out of pocket, though it is considered a lower-intensity statin than Livalo.
Pros
Available as a low-cost generic, often $10 to $30 a month without insurance, versus Livalo's $315 to $410
Backed by decades of outcomes data showing reduced heart attack, stroke, and cardiovascular death
Only two dose strengths to titrate between, a simple regimen
Long safety track record dating back to its 1991 FDA approval
Cons
Considered a lower-intensity statin, producing smaller LDL-C reductions than Livalo at its higher doses
No longer sold as a brand-name product in the US, only generic pravastatin is available
Its own trials reported higher rates of musculoskeletal pain and upper respiratory infection
Not specifically labeled for mixed dyslipidemia the way Livalo is
Livalo
Livalo offers a broader labeled use for mixed dyslipidemia and minimal CYP3A4 interaction, making it a reasonable option for patients on multiple medications. It remains brand-only, so monthly costs run far higher than generic pravastatin, and it carries the same rare muscle and liver risks seen across the statin class.
Pros
FDA-approved specifically for mixed dyslipidemia, a broader lipid-lowering label than Pravachol
Minimal metabolism through CYP3A4, leading to fewer drug interactions than many other statins
No FDA boxed warning, with flexible 1 mg to 4 mg dosing for fine-tuning LDL control
Bioequivalent alternative (Zypitamag) exists for a lower-cost pitavastatin option
Cons
Only available as a brand-name drug, typically $315 to $410 a month without insurance
Contraindicated with cyclosporine and dose-limited when combined with erythromycin or rifampin
Rare cases of discontinuation due to elevated creatine phosphokinase at the 4 mg dose
Lacks the multi-decade cardiovascular outcomes trial data that Pravachol has accumulated
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.